Anika Will Re-analyze Unfavorable Orthovisc Data, Look To Pipeline Products
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb's Zimmer unit will continue to sell Anika Therapeutics' Orthovisc outside the U.S. and take a wait-and-see approach toward its contractual obligations in the U.S. while Anika analyzes unfavorable data generated in Phase III U.S. trials.